1. FDA. Sutent Medication Guide (http://www.fda.gov/downloads/drugs/drugsafety/ucm219111.pdf) [PDF]. www.FDA.gov: Pfizer; 2013 [updated August 2013; cited 2014 13th May]. http://www.fda.gov/downloads/drugs/drugsafety/ucm219111.pdf.
2. Clinicaltrials.gov. List results, search of sunitinib http://www.clinicaltrials.gov/ct2/results?termsunitinib 2014 [cited 20/10/2014]. http://www.clinicaltrials.gov/ct2/results?term=sunitinib&recr=Open.
3. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;DB Mendel;Clin Cancer Res,2003
4. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib;BB Hasinoff;Mol Pharmacol,2008
5. Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis;EM Ibrahim;Int J Clin Oncol,2013